<p>Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positive patients.</p>

Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positive patients.

MET-Amplified Lung Cancer: A New Target for XALKORI?

Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.

Share MET-Amplified Lung Cancer: A New Target for XALKORI?

Sign up to save your podcasts

MET-Amplified Lung Cancer: A New Target for XALKORI?

MET-Amplified Lung Cancer: A New Target for XALKORI?

More shows like GRACEcast Radiation Oncology Audio

GRACEcast Head and Neck Cancer Audio

GRACEcast Lung Cancer Video

GRACEcast Radiation Oncology Video

GRACEcast Pancreatic Cancer Audio

GRACEcast Pancreatic Cancer Video

GRACEcast Cancer 101 Audio

GRACEcast Bladder Cancer Video

GRACEcast Head and Neck Cancer Video NEW

GRACEcast Cancer 101 Video